Amcor Completes One-for-Five Reverse Stock Split

Amcor (NYSE: AMCR) completed a 1-for-5 reverse stock split, effective with trading on a split-adjusted basis on January 16, 2026.

Rhea-AI Summary

Amcor (NYSE: AMCR) completed a 1-for-5 reverse stock split, effective with trading on a split-adjusted basis on January 16, 2026.

The split was approved by shareholders on November 6, 2025, and the memorandum of association amendment was filed on January 14, 2026. Amcor ordinary shares continue trading under AMCR on the NYSE with a new CUSIP G0250X149. CHESS Depositary Interests continue trading under AMC on a split-adjusted basis. Computershare is acting as exchange agent; registered U.S. shareholders and CDI holders have specified contact numbers for exchange questions. More details are available in Amcor's September 23, 2025 proxy and on its investor website.

Positive

• Completed a 1-for-5 reverse split effective Jan 16, 2026
• New NYSE CUSIP G0250X149 established for ordinary shares

Negative

• Shares consolidated at a 1-for-5 ratio, which may reduce share count
• Potentially lower liquidity due to split-adjusted trading (immediate effect)

Argus Jan 15 session

+0.14% close to close 1.2x rel. volume Open Argus

Details

News Market Reaction – AMCR

On Jan 15, the day this news came out, AMCR closed 0.14% above the previous close.

Data tracked by StockTitan Argus for the Jan 15 session.

Key Figures

Chromium Xo price: $25,000 Cell capture rate: 80% Gene sensitivity uplift: 40% +2 more

Chromium Xo price

$25,000

U.S. list price for single cell instrument

Cell capture rate

80%

GEM-X 3' assay maximum cell capture

Gene sensitivity uplift

40%

Higher gene sensitivity vs non-10x methods

Sequencing cost savings

50%

Potential savings vs non-10x methods

Target cost per sample

$100

Goal for high-performance single cell analysis per sample

Historical Context

5 past events · Latest: Dec 11

5 events

1. Dec 11

   Reverse split plan

   24h Move

   -1.2%

   Announced timing and mechanics of 1-for-5 reverse stock split.

2. Nov 18

   Innovation initiative

   24h Move

   +0.1%

   Launched Lift-Off challenge to source sustainable packaging technologies.

3. Nov 05

   Quarterly earnings

   24h Move

   +2.5%

   Reported strong Q1 growth, synergies and reaffirmed fiscal 2026 guidance.

4. Oct 27

   Sustainability report

   24h Move

   +1.6%

   Released FY25 sustainability metrics showing progress on circularity and emissions.

5. Oct 22

   Earnings scheduling

   24h Move

   +1.1%

   Announced timing and access details for Q1 2026 results call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

single cell analysis, spatial biology, sequencing, ffpe

4 terms

single cell analysis medical

"Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis."

A laboratory method that examines individual cells one by one to measure their genes, proteins or activity, rather than averaging results across many cells. For investors, it matters because this fine-grained view can reveal hidden subpopulations, pinpoint more precise drug targets, improve diagnostic tests and reduce development risk—think of inspecting each brick in a wall to find the ones that need repair instead of judging the wall as a whole.

spatial biology medical

"10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo,"

Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.

sequencing technical

"GEM-X technology also enables researchers to generate more usable reads to detect more genes with less sequencing, potentially saving more than 50% on sequencing costs"

Sequencing is the laboratory process that reads the exact order of the building blocks in DNA or RNA, like reading the letters in a book that make up a living organism’s instruction manual. For investors, sequencing matters because it powers diagnostics, drug discovery and personalized medicine — similar to how having a detailed map lets a company target opportunities more precisely, which can change revenue potential and regulatory risk.

ffpe medical

"upgrade to Chromium X to access the full breadth of the company's single cell portfolio, including assays for FFPE samples and immune profiling."

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZURICH, Jan. 15, 2026 /PRNewswire/ -- Amcor plc (NYSE: AMCR; ASX: AMC), a global leader in developing and producing responsible packaging solutions, announced today it has completed its previously announced 1-for-5 reverse stock split.

The reverse stock split was approved by Amcor shareholders at its annual general meeting of shareholders held on November 6, 2025.  Amcor filed an amendment to its memorandum of association to effect the reverse stock split on January 14, 2026.

Amcor ordinary shares began trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") today and shares continue to trade under the symbol "AMCR" with a new CUSIP number, which is G0250X 149.  Amcor's CHESS Depositary Interests ("CDIs") continue to trade under the symbol "AMC" and are also now trading on a split-adjusted basis.

Amcor's transfer agent, Computershare, is acting as exchange agent for the reverse stock split. Registered U.S. shareholders who hold their shares directly may contact Computershare toll free at 1-866-526-3029 (within the U.S.), or at 1-617-668-3920.  Holders of CDIs may contact Computershare toll free at 1300 850 505 (within Australia) or at +61 3 9415 4000 (outside of Australia).  If you hold your shares with a broker, queries should be directed to your broker.

Additional information concerning the reverse stock split can be found in Amcor's definitive proxy statement filed with the Securities and Exchange Commission on September 23, 2025, as well as on Amcor's Investor Relations website, https://www.amcor.com/investors.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons, and closures, that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC

www.amcor.com  I  LinkedIn  I  YouTube

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amcor (AMCR) announce about a reverse stock split on January 16, 2026?

Amcor completed a 1-for-5 reverse stock split; shares began trading split-adjusted on Jan 16, 2026.

When was the Amcor (AMCR) reverse split approved by shareholders?

Shareholders approved the 1-for-5 reverse split at the annual meeting on November 6, 2025.

Did Amcor change its CUSIP after the reverse split and what is it?

Yes; Amcor ordinary shares now trade under CUSIP G0250X149 on the NYSE.

Are Amcor CHESS Depositary Interests (AMC) affected by the reverse split?

Yes; CHESS Depositary Interests continue trading under AMC and are now split-adjusted.

Who is the exchange agent for Amcor's reverse stock split and how can shareholders contact them?

Computershare is acting as exchange agent; U.S. registered shareholders can call 1-866-526-3029 or 1-617-668-3920.